Aeolus Pharmaceuticals Secures European Patents for AEOL 10150 and Pipeline Compounds.LAGUNA NIGUEL, Calif. -- Aeolus Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AOLS (All-Optical Label Switching) An optical packet switching technology that tags data streams with optical labels (headers). AOLS splits off and analyzes the label using electronic circuits in initial systems (photonic circuits are expected later). ) announced today that it has secured patent protection via the European Patent Office for its patents disclosing and claiming its lead clinical compound, AEOL 10150, and its Pipeline compounds, including AEOL 11207. Having passed the required European patent opposition period unopposed, the European patents that claim AEOL 10150 (pending through January 25, 2020) and AEOL 11207 and other members of the Pipeline series (pending through April 23, 2019) are now claimed in issued patents in the following European countries: Germany, Denmark, Spain, France, the United Kingdom, Ireland, Italy and Sweden. Aeolus is developing a variety of therapeutic agents based on its library of 200 proprietary small molecule catalytic antioxidants Antioxidants Substances that reduce the damage of the highly reactive free radicals that are the byproducts of the cells. Mentioned in: Aging, Nutritional Supplements antioxidants, n. , with AEOL 10150 being the first Aeolus compound to enter human clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy . The Aeolus compounds have shown the ability to scavenge scav·enge v. scav·enged, scav·eng·ing, scav·eng·es v.tr. 1. To search through for salvageable material: scavenged the garbage cans for food scraps. 2. a broad range of reactive oxygen species reactive oxygen species, n molecules and ions of oxygen that have an unpaired electron, thus rendering them extremely reactive. Many cellular structures are susceptible to attack by ROS contributing to cancer, heart disease, and cerebrovascular disease. , or free radicals, which lead to oxidative stress oxidative stress, n an imbalance of the prooxidant antioxidant ratio in which too few antioxidants are produced or ingested or too many oxidizing agents are produced. . Oxidative stress is implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in over 100 diseases and disorders. As catalytic antioxidants, Aeolus' proprietary compounds mimic and thereby amplify the body's natural enzymatic systems for eliminating free radicals, thereby reducing the damaging impact of oxidative stress. The Aeolus Pipeline Initiative, which focuses on the Pipeline compounds, began in the third calendar quarter of 2005, and is an internal development program focused on advancing several of Aeolus' most promising catalytic antioxidant antioxidant, substance that prevents or slows the breakdown of another substance by oxygen. Synthetic and natural antioxidants are used to slow the deterioration of gasoline and rubber, and such antioxidants as vitamin C (ascorbic acid), butylated hydroxytoluene compounds, including AEOL 11207. The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Please visit our website at www.aeoluspharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion